BIM technology helps Precis articulate complex engineering concepts and streamline the design process
Precis Engineering, Inc. is providing mechanical, electrical, plumbing (MEP) and process engineering and commissioning services for Morphotek, Inc.’s new $80 million, 60,000 square foot manufacturing pilot plant, under construction on Welsh Road in Exton, Pennsylvania.
The Morphotek facility will house a biologics plant, laboratories, cGMP cell culture core area, warehouse storage, and offices to support the company’s production of biologics for early-stage clinical trials. Completion is planned for spring 2011 with operations beginning in 2012.
“The building’s design will tell the story of Morphotek’s research and development toward new treatments for cancer and other diseases,” said Precis principal Robert Dick, PE. “Glass-walled corridors will provide unprecedented access to view clean rooms, production suites, and mechanical systems in operation. The design will let executives tour the facility without having to put on clean-room garments.”
Precis developed the engineering design using Autodesk Revit MEP software, a relatively new Building Information Modeling (BIM) tool with strong three-dimensional coordination abilities. The design team, including Precis and Arcus Design Group Architects, Inc., has used the new software to streamline the design and decision-making processes. In addition, Precis has generated three-dimensional animated videos that illustrate how the finished facility will look and how its state-of-the-art systems will function.
The Morphotek pilot plant has been designed to achieve LEED (Leadership in Energy and Environmental Design) certification at the Silver level or higher.
To request additional information about the project, please contact Murray Sterling at 215.540.9800 extension 286.
About Morphotek
Morphotek®, Inc., a subsidiary of Tokyo-based Eisai Co., Ltd., is a biopharmaceutical company specializing in the development of protein and antibody products through the use of novel and proprietary technologies. The technologies have been successfully applied to a variety of molecules that are suitable for pharmaceutical product development in the areas of antibody therapeutics, protein therapeutics, product manufacturing, drug target discovery, and improved output traits for commercial applications. The company is currently focusing its platform on the development and manufacturing of therapeutic antibodies for the treatment of cancer, inflammation and infectious disease. For more information, please visit www.morphotek.com.
Images courtesy Arcus Design Group Architects, Inc.